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Vasopressin: A look at dialysis 
hypertension and autonomic 
dysfunction
MJ Flanigan1,2
Dialysis hypertension is a complex disorder in which ambient vascular 
resistance is too high for the blood volume. van der Zee et al. remind us 
that this is contingent upon the endothelium itself, and that endothelial 
dysfunction is integral to uremia. Thus, while vasopressin may not abolish 
dialysis hypotension, its effects highlight the influence of uremia on the 
autocrine and neuroendocrine control of cardiovascular physiology.
Kidney International (2007) 71, 285–287. doi:10.1038/sj.ki.5002114
1University of Iowa Hospitals and Clinics, 
Department of Medicine, Iowa City, Iowa, USA; and 
2Marshfield Clinic Lakeland Center, Department of 
Nephrology, Minocqua, Wisconsin, USA.
Correspondence: MJ Flanigan, Marshfield Clinic 
Lakeland Center, 9601 Townline Rd, Minocqua, 
Wisconsin 54548,USA. 
E-mail: flanigan.michael@marshfieldclinic.org
In view of the increasing incidence of 
FSGS, it is appropriate to ask whether 
this lesion is part of the minimal change–
FSGS continuum. Th e absence of epithe-
lial-cell proliferation, activated parietal 
cells, podocyte dedifferentiation, and 
periglomerular and tubulointerstitial 
fi brosis suggests a diff erent pathological 
process than what has been described for 
FSGS.9–11 Nevertheless, it is intriguing 
that the glomerular changes were detected 
in refractory INS patients and not in non-
proteinuric controls. Additional studies 
are therefore required to describe the 
pathogenesis of this lesion. And fi nally, 
despite the lack of predictive value of 
microglomeruli in congenital nephrotic 
syndrome, it is important to determine 
whether these lesions are harbingers of 
chronic kidney disease.12 Longitudinal 
evaluation of this cohort may provide 
insights into histological progression.
Several years ago, in a Kidney Interna-
tional editorial addressing the increas-
ing incidence of FSGS in children, one 
author presciently remarked, “Th e more 
one reads and asks, the more apparent our 
lack of understanding becomes; we know 
very little about INS in childhood.”12 Sub-
sequent studies have consistently demon-
strated a more severe form of histology 
underlying childhood INS. Th e clinical 
significance of the glomerular lesions 
described by Dijkman et al.6 and by other 
researchers in these patients would be best 
addressed by a prospective multicenter 
study sufficiently powered to evaluate 
contemporary risk factors and clinically 
appropriate end points — in other words, 
an ISKDC for the new millennium.
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Hemodialysis is an empiric therapy 
encumbered by two dominating complica-
tions: hypertension and ‘dialysis discom-
fort’. Between 60% and 90% of patients 
initiating dialysis are hypertensive,1 and 
vascular disease inclusive of sudden death, 
myocardial infarction, stroke, and conges-
tive heart failure accounts for approxi-
mately 50% of dialysis patient mortality.2 
Since the inception of maintenance dial-
ysis, blood pressure control has been an 
essential goal of therapy. Dialysis pioneers 
assumed that kidney disease was a form 
of ‘salt-sensitive hypertension’ that would 
respond to normalization of total body 
sodium. Thus, early dialysis prescrip-
tions combined vigorous dietary sodium 
restriction with hyponatremic dialysate 
to achieve this goal. Th is controlled blood 
pressure but provoked dialysis disequilib-
rium and discomfort. As dialyzers became 
more durable, ultrafi ltration became the 
primary means of regulating extracellu-
lar volume and total body sodium. Physi-
cians attempted to achieve normal blood 
pressure by achieving the lowest postdi-
alysis weight possible without incurring 
symptomatic hypotension, referring to 
this weight as the ‘dry’ or ‘target’ weight. 
In the past two decades, high-effi  ciency 
dialysis combined with transmembrane 
ultrafiltration has become the rule in 
maintenance hemodialysis, but as a con-
sequence the most common therapeutic 
complications are interdialytic hyperten-
sion and intradialytic hypotension.
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tion of dialysis hypotension adds to our 
understanding of uremia and yields viable 
hypotheses that a retained toxin is capable 
of influencing blood pressure control, 
sympathetic tone, baroreceptor sensitivity, 
hypothalamic–pituitary interaction, and 
dialysis ultrafiltration tolerance.
Intradialytic hypotension is a fall in 
blood pressure during hemodialysis. It 
occurs in the setting of an elevated periph-
eral vascular resistance, is a manifestation 
of insufficient cardiac output, responds to 
restored cardiac filling, and, when symp-
tomatic and recurrent, identifies a group 
of patients with underlying cardiovascu-
lar disease and excess early mortality.12,18 
Perhaps disordered nitric oxide metabo-
lism is an important participant in uremic 
autonomic dysfunction, salt sensitiv-
ity, hypertension, hypothalamic–pituitary 
dysfunction, and cardiovascular disease. 
These are testable hypotheses, and we might 
expect that increased dialysis frequency 
and/or dialysis dose would correct these 
abnormalities.19–21 Alternatively, asym-
metric dimethylarginine and nitric oxide 
synthase may point to a more fundamental 
abnormality in a yet unexplored intracel-
lular signal transducer.22
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with dialysis the removal of water-soluble 
toxins would de purate, detoxify, reverse ure-
mic symptoms, and recover the individual. 
Asymmetric dimethylarginine is a candidate 
uremic toxin.7,8 Excess retained asymmetric 
dimethylarginine inhibits endothelial and 
neuronal nitric oxide synthase, contributing 
to increased vascular resistance and sympa-
thetic tone. In the central nervous system, 
inhibition of endogenous hypothalamic 
nitric oxide suppresses vasopressin release, 
is implicated in salt-sensitive hypertension,9 
and may be responsible for the imbalance 
between sympathetic and parasympathetic 
tone noted in uremic subjects.10
Dialysis removes circulating nitric oxide 
synthase inhibitors and enhances nitric 
oxide generation. This results in unop-
posed resistance vessel relaxation and 
plasma volume sequestration. Unless 
endogenous nitric oxide synthase inhibi-
tors such as vasopressin are released in 
response to baroreceptor stimulation, 
resistance vessels will be hyporesponsive 
to adrenergic and sympathetic stimula-
tion, and hypotension will occur with a 
lesser absolute decrement in total blood 
volume. If this mechanism is instrumen-
tal to dialysis hypotension, then vasopres-
sin infusion should reset the relationship 
between ultrafiltered volume and hypo-
tension. Such are the findings of van der 
Zee et al.3
This does not address the question of 
why, during dialysis-induced hypotensive 
shock, there is no vasopressin release until 
nausea and/or symptomatic collapse (via 
the Bezold-Jarisch reflex) ensues. Are the 
findings of altered hypothalamic–pitu-
itary function a result of suppressed neu-
ronal nitric oxide synthase activity or a 
product of altered baroreceptor set point 
and sensitivity? Dialysis hypertension is a 
manifestation of sympathetic hyperactivity 
and of plasma volume expansion.10 There 
are ample suggestions of impaired hypo-
thalamic sympathetic–parasympathetic 
integration11,12 as well as endothelial and 
neurotransmitter dysfunction9,13,14 in dial-
ysis patients. Further, the kidney may be an 
integral component of dialysis hyperten-
sion,8,15,16 and hypothalamic contribu-
tions to dialysis hypertension appear to 
be modulated by dietary sodium.9,17 Our 
understanding of dialysis hypertension 
is incomplete, but the current explora-
Van der Zee et al.3 (this issue) report a 
careful series of clinical investigations that 
expands our knowledge of dialysis hypo- 
and hypertension. They confirm that exog-
enous vasopressin administration produces 
identical changes in the plasma vasopressin 
levels of dialysis and nondialysis subjects, 
showing that vasopressin is neither removed 
nor degraded by hemodialysis. Further, they 
show that dialysis ultrafiltration does not 
regularly stimulate vasopressin release,4,5 
and that administration of exogenous vaso-
pressin improves ultrafiltration tolerance in 
stable hypertensive hemodialysis subjects.
Although van der Zee et al.3 demon-
strate that with administration of vaso-
pressin the dialysis weight loss of stable 
hemodialysis patients can be increased 
by one-half kilogram without incurring 
intradialysis hypotension, it is unlikely 
that vasopressin will find widespread clin-
ical use in maintenance dialysis therapy. 
This is because the patients who received 
vasopressin were not free of dialysis-relat-
ed hypotension but rather deferred their 
blood pressure nadir into the postdialysis 
recovery period. Rather, these experiments 
are exciting because they refocus our 
attention on a novel mechanism that may 
explain numerous earlier observations 
about dialysis hyper- and hypotension.
It is not surprising that vasopressin alters 
the endothelial responsiveness of small resis-
tance vessels and thus limits vascular pool-
ing, improves cardiac refilling, and restores 
cardiac output during dialysis. In the periph-
eral circulation the vasopressin V1a receptor 
is an important modulator of baroreceptor 
sensitivity6 and endothelial-cell function. 
Vasopressin antagonizes endogenous and 
exogenous nitric oxide through a cyclic 
guanosine monophosphate-stimulated 
release of intracellular calcium stores. Thus 
vasopressin and nitric oxide are antagonists 
that affect vascular resistance in a number 
of pathological settings in which excessive 
endothelial nitric oxide synthase activity 
is present. Uremia is a construct proposed 
in the nineteenth century to explain the 
systemic illness of renal disease. This con-
struct fundamentally postulated that small-
molecular weight metabolites of protein 
metabolism would accumulate in renal fail-
ure, disrupt normal biochemical reactions, 
and produce toxicity or poisoning. In con-
cert with this postulate, it was proposed that 
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